{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:46:57Z","timestamp":1783529217763,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.medj.2025.100640","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T14:35:34Z","timestamp":1744382134000},"page":"100640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-9715","authenticated-orcid":false,"given":"Antoine","family":"Enfrein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric A.","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100640_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis","author":"Furie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100640_bib2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100640_bib3","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2025.100640_bib4","unstructured":"New ACR Guideline Summary: Lupus Nephritis https:\/\/rheumatology.org\/press-releases\/new-acr-guideline-summary-provides-guidance-to-screen-treat-and-manage-lupus-nephritis."},{"key":"10.1016\/j.medj.2025.100640_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000533","article-title":"Absence of renal remission portends poor long-term kidney outcome in lupus nephritis","volume":"8","author":"Pirson","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.medj.2025.100640_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medj.2025.100640_bib7","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.medj.2025.100640_bib8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.medj.2025.100640_bib9","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2665-9913(21)00418-5","article-title":"Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients","volume":"4","author":"Boekel","year":"2022","journal-title":"Lancet. Rheumatol."},{"key":"10.1016\/j.medj.2025.100640_bib10","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.medj.2025.100640_bib11","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.medj.2025.100640_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N.\u00a0Engl. J. Med. Overseas. Ed."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T19:13:46Z","timestamp":1745003626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666634025000674"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100640","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100640"}}